YKYoshiaki Kitamura

Yoshiaki Kitamura

*This is an algorithmically generated author record based on publicly available information.

Yoshiaki Kitamura has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Proposal of a Pharmacokinetic/pharmacodynamic (PK/PD) Index Map for Selecting an Optimal PK/PD Index from Conventional Indices (AUC/MIC, Cmax/MIC, and TAM) for Antibiotics

    by Yoshiaki Kitamura, Kenta Yoshida, Makiko Kusama, Yuichi Sugiyama

    A pharmacokinetic/pharmacodynamic (PK/PD) analysis is important in antibiotic chemotherapy. Basically, the in vivo efficacy of antibiotics that exert concentration-dependent effects can be predicted using conventional PK/PD indices such as the ratio of the area under the curve to the minimum inhibitory concentration (AUC/MIC) and/or the ratio of the maximum plasma concentration to MIC (Cmax/MIC), whereas that of antibiotics with time-dependent effects can be determined using the period of time for which the drug concentration exceeds the MIC (time above MIC [TAM]). However, an optimal PK/PD index remains to be established for some antibiotics. Thus, a PK/PD model which describes the PK profile and effect of an antibiotic was developed, and the results obtained from this model were interpreted to form a PK/PD index map to assess the optimal PK/PD index for the antibiotic. The findings from the map were generally consistent with clinical outcomes even for the antibiotics which proved to be exceptions to the conventional classification. For example, AUC/MIC was an optimal index for azithromycin despite its time-dependent bactericidal activity, and Cmax/MIC was a poor index for arbekacin despite its concentration-dependent profile. Thus, the map would be useful for selecting the appropriate PK/PD index for an antibiotic.


  • Relationship Between the Urinary Excretion Mechanisms of Drugs and Their Physicochemical Properties

    by Sumito Ito, Hirotaka Ando, Atsushi Ose, Yoshiaki Kitamura, Tomohiro Ando, Hiroyuki Kusuhara, Yuichi Sugiyama


  • Hepatic Uptake in the Dog: Comparison of Uptake in Hepatocytes and Human Embryonic Kidney Cells Expressing Dog Organic Anion-Transporting Polypeptide 1B4

    by Alison J. Wilby, Kazuya Maeda, Paul F. Courtney, Yasuyuki Debori, Peter J. H. Webborn, Yoshiaki Kitamura, Hiroyuki Kusuhara, Rob J. Riley, Yuichi Sugiyama

    Although the dog is frequently used in pharmacological, pharmacokinetic, and drug safety studies, little is known about canine drug transporters. Dog organic anion-transporting polypeptide (Oatp1b4) has recently been cloned (Comp Biochem Physiol C Toxicol Pharmacol 151:393–399, 2010), but the contribution of Oatp1b4 to hepatic uptake has yet to be clarified. This study compares the transport characteristics of dog Oatp1b4 with those of human OATP1B1/1B3 and demonstrates the importance of Oatp1b4 in the uptake of anionic compounds in dog hepatocytes. Oatp1b4 is the predominant Oatp in dog liver with expression levels double and 30 times those of Oatp2b1 and Oatp1a2, respectively. Uptake of a range of typical OATP substrates by Oatp1b4-expressing HEK293 cells was compared with that in fresh dog hepatocytes. All compounds tested were transported by Oatp1b4 and uptake intrinsic clearance (CLint, uptake) in dog hepatocytes in sodium-free buffer was correlated significantly with CLint, uptake in Oatp1b4-expressing cells. Dog in vivo clearance for five substrates was predicted more accurately from CLint, uptake than from metabolic intrinsic clearance (CLint, met), indicating that uptake governs the overall in vivo hepatic clearance of these anionic compounds in dog. The substrate specificities of dog Oatp1b4 appear to be similar to those of human OATP1B1/OATP1B3, whereas the relative uptake clearance of substrates for Oatp1b4 correlate better with OATP1B3 than with the more abundant hepatic analog OATP1B1.


  • Prorocentrol, a Polyoxy Linear Carbon Chain Compound Isolated from the Toxic Dinoflagellate Prorocentrum hoffmannianum

    by Kohtaro Sugahara, Yoshiaki Kitamura, Michio Murata, Masayuki Satake, Kazuo Tachibana

    A polyoxy linear carbon chain compound, prorocentrol (1), was isolated from cultured cells of the dinoflagellate Prorocentrum hoffmannianum, which produces a polyether carboxylic acid, okadaic acid. The structure of 1 was elucidated by detailed analyses of 2D NMR spectra. Compound 1 possesses 30 hydroxy groups, 1 ketone, and 8 double bonds on the C65-linear carbon chain. Its partial relative configuration was deduced by the proton−proton and long-range carbon−proton coupling constants, and compound 1 showed moderate cytotoxicity and antidiatom activity.


  • Design, Synthesis, and Structure−Activity Relationship Studies of Novel 2,4,6-Trisubstituted-5-pyrimidinecarboxylic Acids as Peroxisome Proliferator-Activated Receptor γ (PPARγ) Partial Agonists with Comparable Antidiabetic Efficacy to Rosiglitazone

    by Shigeki Seto, Kyoko Okada, Koichi Kiyota, Shigeki Isogai, Maki Iwago, Takehiro Shinozaki, Yoshiaki Kitamura, Yasushi Kohno, Koji Murakami

    A series of novel 2,4,6-trisubstitutedpyrimidine-5-carboxylic acid derivatives were designed and synthesized with the intent of producing a peroxisome proliferator-activated receptor γ (PPARγ) partial agonist for antidiabetic agents. A pharmacophore-driven approach of in-house screening identified compound 7, which led to the identification of compound 9 featuring a 2,4,6-trisubstituted pyrimidine-5-carboxylic acid core. Structure−activity relationship studies of 9 resulted in identifying 4,6-bisbenzylthio-2-methylthiopyrimidine-5-carboxylic acid (50) as the most attractive of all the screened compounds. The X-ray cocrystal structure of 50 bound on PPARγ revealed that the key hydrogen bond interactions, which are not related to the activation function 2 (AF-2) site, are different from those of the full agonist. Compound 50 showed typical PPARγ partial agonist properties in the PPARγ-GAL4 functional assay and weaker differentiation of adipocytes in 3T3-L1 cells than observed with rosiglitazone. Furthermore, 50 displayed comparable antidiabetic efficacy with rosiglitazone in db/db mice, although its potency is 10-fold weaker than that of rosiglitazone.


  • Basolateral Efflux Mediated by Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3) Facilitates Intestinal Absorption of Folates in Mouse

    by Yoshiaki Kitamura, Hiroyuki Kusuhara, Yuichi Sugiyama

    Purpose This study investigated the role of an ABC transporter, Mrp3/Abcc3 in intestinal folate absorption. Methods Plasma concentrations of folic acid and leucovorin, given orally, were determined in wild-type and Mrp3 −/− mice. Mucosal-to-serosal transport was determined in the everted intestinal sacs. The plasma concentrations of endogenous 5-methyltetrahydrofolic acid, homocysteine and vitamin B12, and mRNA levels of hepatic and intestinal folate metabolizing enzymes were compared between wild-type and Mrp3 −/− mice. Results C max and area-under plasma concentration–time curve of folic acid were 3.0- and 2.3-fold lower in Mrp3−/− mice compared with wild-type mice, whereas the total body clearance was unchanged. Absorption of leucovorin was significantly delayed in Mrp3−/− mice. Mucosal-to-serosal transport of folic acid and leucovorin was significantly decreased in the duodenum of Mrp3−/− mice, where their PS serosal was decreased to 6.3 and 22% of that in wild-type mice, respectively. PS serosal of 5-methyltetrahydrofolic acid was moderately decreased in Mrp3−/− mice. There was no obvious abnormality in folate homeostasis in Mrp3−/− mice. Conclusions Mrp3 accounts for the serosal efflux of folic acid and leucovorin, while it makes a moderate contribution to the serosal efflux of 5-methyltetrahydrofolic acid in mice. Mrp3 dysfunction does not disrupt folate homeostasis in mouse.


  • Open Access

    Functional Characterization of Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3) in the Basolateral Efflux of Glucuronide Conjugates in the Mouse Small Intestine

    by Yoshiaki Kitamura, Hiroyuki Kusuhara, Yuichi Sugiyama

    The intestine expresses metabolic enzymes and transporters and functions as a barrier to orally administered xenobiotics. This study aimed to examine the importance of multidrug resistance-associated protein 3 (Mrp3/Abcc3) in the serosal efflux of glucuronide conjugates formed in the intestine using wild-type and Mrp3(−/−) mice. The everted sacs of the intestine were incubated with 4-methylumbelliferone (4MU), and the efflux rates of intracellularly formed glucuronide conjugate of 4MU (4MUG) into the mucosal and serosal sides were determined. The permeability-surface area product across the serosal membrane (PSserosal) of 4MUG in wild-type mice was greatest in the duodenum followed by the jejunum, ileum, and colon. The corresponding parameters were significantly reduced in Mrp3(−/−) mice (approximately 33% of that in wild-type mice) except for the colon where the PSserosal of 4MUG was similar between wild-type and Mrp3(−/−) mice. There was no difference in the PSmucosal of 4MUG in whole segments of the intestine between wild-type and Mrp3(−/−) mice. In addition to 4MUG, the PSserosal of the glucuronide conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) and acetaminophen in the jejunal everted sacs were also significantly reduced in Mrp3(−/−) mice compared with wild-type mice. There was no difference in the mRNA and protein expression of efflux transporters between wild-type and Mrp3(−/−) mice. These results suggest that Mrp3 plays major roles in the efflux transport of various glucuronide conjugates from the enterocytes to the portal blood in the small intestine together with unknown transporter(s), but the contribution of Mrp3 to the basolateral efflux of 4MUG was negligible in the colon.


  • Prediction of Human Bioavailability from Human Oral Administration Data and Animal Pharmacokinetic Data Without Data from Intravenous Administration of Drugs in Humans

    by Haruo Imawaka, Kiyomi Ito, Yoshiaki Kitamura, Kiyoshi Sugiyama, Yuichi Sugiyama

    To predict the absolute oral bioavailabilities (BAs) of drugs in humans without using pharmacokinetic data from intravenous administration in humans. The distribution volume of the terminal phase ( \({\text{Vd}}_{\beta } \) ) in humans was predicted by three methods using animal pharmacokinetic data. Then, total body clearance (CLtot) was calculated by multiplying the elimination rate constant and \({\text{Vd}}_{\beta } \) , and the BA was calculated as a ratio between CLtot and oral clearance. The predicted and observed values were compared for 67 drugs for which pharmacokinetic data after intravenous administration in humans were available. For \({\text{Vd}}_{\beta } \) , predicted values within twice the observed value were obtained for 72.1% of drugs by both methods Ia and Ib, respectively, in which only rat pharmacokinetic data were used. The corresponding percentage was 75.0% for method II, in which pharmacokinetic data from animals other than rats were used. For BA, predicted values within 1.3 times the observed values were obtained for 66.7% and 57.4% of drugs by methods Ia and Ib, respectively, and 75.0% by method II. Using the present methods, it is possible to predict BA from human oral administration data combined with animal pharmacokinetic data to a certain level without using intravenous injection data.


  • Identification of anFTortholog in Japanese apricot (Prunus mumeSieb. et Zucc.)

    by T. Esumi, C. Hagihara, Y. Kitamura, H. Yamane, R. Tao

    PmFT, a Prunus mume ortholog of FT (FLOWERING LOCUS T) in Arabidopsis thaliana (L.) Heynh., was isolated and characterised to elucidate the mechanism of floral bud formation in Japanese apricot (P. mume). The Japanese apricot genome contained a single locus of PmFT. PmFT consisted of a 1,473-bp open reading frame with three introns and four exons, which encoded 174 amino acid residues. The PmFT sequence showed high identity to A. thaliana FT and to FT orthologs in other plant species. Wild-type and ft-1 strains of Arabidopsis that were transformed with 35S:PmFT showed precocious flowering, indicating that PmFT has the same function as A. thaliana FT and FT orthologs in other plant species. PmFT transcripts were found in all tissues examined, with more abundant expression observed in tissues from adult trees than from seedlings.


  • Increasing Systemic Exposure of Methotrexate by Active Efflux Mediated by Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3)

    by Yoshiaki Kitamura, Masakazu Hirouchi, Hiroyuki Kusuhara, John D. Schuetz, Yuichi Sugiyama

    The aim of this study was to investigate the functional importance of multidrug resistance-associated protein (Mrp)3/Abcc3 and Mrp4/Abcc4 in the pharmacokinetics of methotrexate. Compared with the corresponding wild-type mice, the plasma concentrations of methotrexate given orally were similar in Abcc4-/- mice and were significantly lower in Abcc3-/- mice. Pharmacokinetic parameters related to hepatobiliary transport were determined under steady-state conditions in wild-type and Abcc3-/- mice that were given a constant intravenous infusion of methotrexate. The biliary clearance, based on the plasma concentration, was 1.6-fold greater in Abcc3-/- mice than in wild-type mice (23 and 15 ml/min/kg, respectively, P < 0.05). Because the basolateral uptake and canalicular efflux clearances of methotrexate were similar in wild-type and Abcc3-/- mice, this result suggests that the basolateral efflux clearance of methotrexate is decreased in the liver of Abcc3-/- mice. Furthermore, a lower fraction of absorption of methotrexate (Fa Fg) was suggested in Abcc3-/- mice (0.49 and 0.29 in wild-type and Abcc3-/- mice, respectively). The mucosal-to-serosal transport rate of methotrexate, determined in vitro using everted sacs, was highest in the duodenum and was significantly decreased in Abcc3-/- mice compared with wild-type mice. This is ascribed to the reduced intrinsic efflux clearance of methotrexate across the serosal membrane (22 and 5.3 μl/min/sac in wild-type and Abcc3-/- mice, respectively, P < 0.05). These results suggest that Mrp3 mediates basolateral efflux of methotrexate in the liver and duodenum, thereby serving to increase systemic exposure, whereas Mrp4 is likely to play only a limited role in the systemic methotrexate exposure.